JP Morgan Chase
NRSN icon

JP Morgan Chase’s NeuroSense Therapeutics NRSN Stock Holding History

JP Morgan Chase’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,304
Closed -$1.9K – 7642
2023
Q2 		$1.9K Buy
+1,304
New +$2.28K ﹤0.01% 6348

Other funds holding NRSN

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

JP Morgan Chase's NRSN Position: Q3 2023 in Review

JP Morgan Chase sold out of NeuroSense Therapeutics (NRSN) in Q3 2023, closing a stake of 1,304 shares — an estimated $1.9K sold.

JP Morgan Chase first reported a position in NRSN in Q2 2023 and held it in 1 quarter. The position peaked at $1.9K in Q2 2023. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2023.

  • JP Morgan Chase reported no remaining NeuroSense Therapeutics position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,304 NeuroSense Therapeutics shares in Q3 2023, an estimated $1.9K.
  • JP Morgan Chase first reported a position in NeuroSense Therapeutics in Q2 2023 and held it in 1 quarter.
  • JP Morgan Chase's NeuroSense Therapeutics position peaked at $1.9K in Q2 2023.
  • 5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.